Validation of the revised Patient Perception of Migraine Questionnaire (PPMQ-R): Measuring satisfaction with acute migraine treatment in clinical trials

Cephalalgia

Volumn 28, Issue 5, 2008, Pages 510-523

  Kimel, M ^a   Hsieh, R ^a   McCormack, J ^a   Burch, S P ^b   Revicki, D A ^a  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Migraine; Questionnaire; Satisfaction; Treatment; Validation

Indexed keywords

NAPROXEN PLUS SUMATRIPTAN; PLACEBO;

ADULT; AGITATION; ARTICLE; BLOOD PRESSURE; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; EMOTIONAL DISORDER; FACE EDEMA; FATIGUE; FEMALE; FLUSHING; HEALTH CARE QUALITY; HEART PALPITATION; HEART RATE; HUMAN; HYPERTENSION; INFECTION; LARYNGITIS; LUNG CONGESTION; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MUSCULOSKELETAL DISEASE; NAUSEA; NERVOUSNESS; NOSE CONGESTION; PARESTHESIA; PATIENT PERCEPTION OF MIGRAINE QUESTIONNAIRE; PATIENT SATISFACTION; PSYCHOMETRY; QUESTIONNAIRE; SIDE EFFECT; SINUSITIS; SOMNOLENCE; SORE THROAT; THORAX PAIN; VALIDATION STUDY; VERTIGO; WORK CAPACITY; XEROSTOMIA;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; MALE; MARYLAND; MIDDLE AGED; MIGRAINE DISORDERS; OUTCOME ASSESSMENT (HEALTH CARE); PAIN MEASUREMENT; PATIENT SATISFACTION; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 41849148290     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2007.01524.x     Document Type: Article

References (30)

1. Shikiar R, Rentz AM. Satisfaction with medication: an overview of conceptual, methodological, and regulatory issues. Value Health 2004 7 : 204 15.
2. Weaver M, Patrick DL, Markson LE, Martin D, Frederic I, Berger M. Issues in the measurement of satisfaction with treatment. Am J Manag Care 1997 3 : 579 94.
3. Revicki DA. Patient assessment of treatment satisfaction: methods and practical issues. Gut 2004 53 (Suppl. 4 iv, 40 4.
4. Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache 2002 42 (Suppl. 1 3 9.
5. Ryan RE Jr. Patient treatment preferences and the 5-HT1B/1D agonists. Arch Intern Med 2001 161 : 2545 53.
6. Pascual J, Bussone G, Hernandez JF, Allen C, Vrijens F, Patel K. Comparison of preference for rizatriptan 10-mg wafer versus sumatriptan 50-mg tablet in migraine. Eur Neurol 2001 45 : 275 83.
7. Pascual J, Munoz R, Leira R. An open preference study with sumatriptan 50 mg and zolmitriptan 2.5 mg in 100 migraine patients. Cephalalgia 2001 21 : 680 4.
8. Davies GM, Santanello N, Lipton R. Determinants of patient satisfaction with migraine therapy. Cephalalgia 2000 20 : 554 60.
9. Caro G, Caro JJ, O'Brien JA, Anton S, Jackson J. Migraine therapy: development and testing of a patient preference questionnaire. Headache 1998 38 : 602 7.
10. Luciani RJ, Osterhaus JT, Gutterman DL. Patient preferences for migraine therapy: subcutaneous sumatriptan compared with other medications. J Fam Pract 1995 41 : 147 52.
11. Baró E, Casado A, García-Cases C, Clerch L, Ribas S. Assessing satisfaction with pain medication in primary care patients: development and psychometric validation of a new measure. Clin Ther 2004 26 : 1124 36.
12. Flood EM, Beusterien KM, Green H, Shikiar R, Baran RW, Amonkar MM, Cella D. Psychometric evaluation of the Osteoporosis Patient Treatment Satisfaction Questionnaire (OPSAT-Q), a novel measure to assess satisfaction with bisphosphonate treatment in postmenopausal women. Health Qual Life Outcomes 2006 4 : 42.
13. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004 6 : 12.
14. Novák A, de la Loge C, Abetz L. Development and validation of an acceptability and satisfaction questionnaire for a contraceptive vaginal ring, NuvaRing. Pharmacoeconomics 2004 22 : 245 56.
15. Davis KH, Black L, Sleath B. Validation of the patient perception of migraine questionnaire. Value Health 2002 5 : 422 30.
16. Revicki DA, Kimel M, Beusterien K, Kwong JW, Varner JA, Ames MH et al. Validation of the revised Patient Perception of Migraine Questionnaire: measuring satisfaction with acute migraine treatment. Headache 2006 46 : 240 52.
17. Patrick DL, Martin ML, Bushmell DM, Pesa J. Measuring satisfaction with migraine treatment: expectations, importance, outcomes, and global ratings. Clin Ther 2003 25 : 2920 35.
18. Kosinski M, Bayliss MS, Bjorner JB, Ware JE, Barber WH, Batenhorst A et al. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 2003 12 : 963 74.
19. Bentler PM. Comparative fit indexes in structural models. Psychol Bull 1990 107 : 238 46.
20. Browne MW, Cudeck R. Alternative ways of assessing model fit. In : Bollen KA, Long JS, eds. Testing structural equation models. Newbury Park, CA : Sage 1993 : 136 62.
21. Kline RB. Principles and practice of structural equation modeling. New York : Guilford Press 2005.
22. Nunnally JC, Bernstein IH. Psychometric theory, 3rd edn. New York : McGraw-Hill 1994.
23. Hays RD, Revicki DA. Reliability and validity (including responsiveness). In : Fayers P, Hays RD, eds. Assessing quality of life in clinical trials, 2nd edn. New York : Oxford University Press 2005 : 25 39.
24. Cohen J. Statistical power analysis for the behavioral sciences, 2nd edn. Hillsdale, NJ : Lawrence Erlbaum Associates 1988.
25. Silberstein S, Goldstein J, Mannix LK, Sheftell F, Byrd S, Ames MH et al. A new migraine therapy: efficacy and tolerability of a fixed single-tablet formulation of sumatriptan RT Technology™ and naproxen sodium in the early intervention paradigm. Headache 2006 46 : 833 [Abstract].
26. Taylor F, Heiring J, Messina E, Michael A, Susan B, McDonald SA, Burch S. Productivity and patient satisfaction benefits of a fixed single-tablet formulation of sumatriptan with RT Technology™ and naproxen sodium in an early intervention paradigm. Headache 2006 46 : 859 [Abstract].
27. MacGregor EA, Brandes J, Eikermann A. Migraine prevalence and treatment patterns: the global Migraine and Zolmitriptan Evaluation survey. Headache 2003 43 : 19 26.
28. Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 1999 2 : 113 27.
29. Revicki DA, Osoba D, Fairclough D, Barofsky I, Berzon R, Leidy NK, Rothman M. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res 2000 9 : 887 900.
30. Food and Drug Administration. Draft guidance for industry on patient-reported outcome measures: use in medical product development to support labeling claims. Fed Regist 2006 71 : 5862.